|
Treatment and prognosis
|
Group A (n = 628)
|
Group B (n = 104)
|
P
|
|---|
|
rTPA
| | | |
0.403
|
| |
No
|
550 (87.6)
|
88 (84.6)
| |
| |
Yes
|
78 (12.4)
|
16 (15.4)
| |
|
Argatroban
| | | |
0.363
|
| |
No
|
521 (83.0)
|
90 (86.5)
| |
| |
Yes
|
107 (17.0)
|
14 (13.5)
| |
|
LMWH
| | | |
0.059*
|
| |
No
|
606 (96.5)
|
96 (92.3)
| |
| |
Yes
|
22 (3.5)
|
8 (7.7)
| |
|
Warfarin
| | | |
0.536*
|
| |
No
|
624 (99.4)
|
103 (99.0)
| |
| |
Yes
|
4 (0.6)
|
1 (1.0)
| |
|
D-Anti-PLT
| | | |
0.852
|
| |
0, no/single
|
290 (46.2)
|
47 (45.2)
| |
| |
1, double
|
338 (53.8)
|
57 (54.8)
| |
|
SILL
| | | |
0.744
|
| |
0, no
|
443 (70.5)
|
75 (72.1)
| |
| |
1, ILL
|
185 (29.5)
|
29 (27.9)
| |
- rTPAvein thrombolysis with recombinant human tissue plasminogen activator. LMWH: Low-molecular-weight heparin. D-anti-PLT (platelets): Aspirin 100 mg or 300 mg + clopidogrel hydrogen sulfate 75 mg; SILL: Intensive lipid-lowering statins. *: Fisher’s exact test (2-sided)
